A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Melanoma (Excluding Uveal Melanoma)|Cervical Carcinoma|Pancreatic Carcinoma|Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative|Hepatocellular Carcinoma|Urothelial Carcinoma|Squamous Cell Carcinoma of the Head and Neck|Nasopharyngeal Carcinoma|Renal Cell Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Non-small Cell Lung Carcinoma|Small Cell Lung Cancer|Gastric or Gastroesophageal Junction Adenocarcinoma|Advanced Solid Tumors|Undifferentiated Pleomorphic Sarcoma
Interventions: BIOLOGICAL: XmAb®23104|BIOLOGICAL: Yervoy® (ipilimumab)
Sponsor: Xencor, Inc.
Collaborators: ICON plc